Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;25(4):127-132.
doi: 10.1007/s11883-023-01091-5. Epub 2023 Mar 2.

Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?

A M Medeiros  1   2 , M Bourbon  3   4
Affiliations
Review

Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?

A M Medeiros et al. Curr Atheroscler Rep. 2023 Apr.

Abstract

Purpose of review: Lipid measurements and genetic testing are the main diagnostic tools for FH screening that are available in many countries. A lipid profile is widely accessible, and genetic testing, although available worldwide, in some countries is only performed in a research context. Still FH is diagnosed late, showing lack of early screening programs worldwide.

Recent findings: Pediatric screening of FH was recently recognized by the European Commission Public Health Best Practice Portal as one on the best practices in non-communicable disease prevention. The early diagnosis of FH and the lowering of LDL-C values over lifespan can reduce the risk of coronary artery disease and offer health and socioeconomic gains. Current knowledge about FH shows that early detection through appropriate screening needs to become a priority in healthcare systems worldwide. Governmental programs for FH identification should be implemented to unify the diagnosis and increase patient identification.

Keywords: Dyslipidemia; FH; FH screening; Familial hypercholesterolemia; High cholesterol; LDLR.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(20):2553–2566. doi: 10.1016/j.jacc.2020.03.057. - DOI - PubMed
    1. Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578–2589. doi: 10.1016/j.jacc.2016.03.520. - DOI - PMC - PubMed
    1. Borén J, John Chapman M, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel Translational medicine. Eur Heart J. 2020;41. - PMC - PubMed
    1. Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, Hovingh GK, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 2018;277:234–255. doi: 10.1016/j.atherosclerosis.2018.08.051. - DOI - PubMed
    1. Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, Dharmayat KI, Freiberger T, Hovingh GK, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Lancet. 2021;398(10312):1713–1725. doi: 10.1016/S0140-6736(21)01122-3. - DOI - PubMed

Publication types